Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Operations (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cash from Operations for 3 consecutive years, with 7682000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 18.45% to 7682000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 30971000.0 through Dec 2025, up 5.67% year-over-year, with the annual reading at 30971000.0 for FY2025, 5.67% up from the prior year.
  • Cash from Operations for Q4 2025 was 7682000.0 at Mereo BioPharma, down from 7309000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 2659000.0 in Q3 2023, with the low at 9420000.0 in Q4 2024.
  • Average Cash from Operations over 3 years is 7078083.33, with a median of 7718000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 382.78% in 2024, then increased 18.45% in 2025.
  • Over 3 years, Cash from Operations stood at 6789000.0 in 2023, then plummeted by 38.75% to 9420000.0 in 2024, then grew by 18.45% to 7682000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 7682000.0, 7309000.0, and 7651000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.